한빛사논문
- 조회311
No-Joon Song,1 Karthik B Chakravarthy,1 Hyeongseon Jeon,1,2 Chelsea Bolyard,1 Kelsi Reynolds,1 Kevin P Weller,1 Sarah Reisinger,3 Yi Wang,1 Anqi Li,1 Sizun Jiang,4,5 Qin Ma,1,2 Dan H Barouch,5 Mark P Rubinstein,1,6 Peter G Shields,3,6 Eugene M Oltz,7 Dongjun Chung,1,2 Zihai Li1,6
1Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, Ohio, USA
2Department of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, Ohio, USA
3The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
4Department of Pathology, Stanford University, Stanford, California, USA
5Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
6Division of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, USA
7Department of Microbial Infection and Immunity, The Ohio State University, Columbus, Ohio, USA
Correspondence to Dr Zihai Li
Abstract
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant is highly transmissible and evades pre-established immunity. Messenger RNA (mRNA) vaccination against ancestral strain spike protein can induce intact T-cell immunity against the Omicron variant, but efficacy of booster vaccination in patients with late-stage lung cancer on immune-modulating agents including anti-programmed cell death protein 1(PD-1)/programmed death-ligand 1 (PD-L1) has not yet been elucidated.
Methods We assessed T-cell responses using a modified activation-induced marker assay, coupled with high-dimension flow cytometry analyses. Peripheral blood mononuclear cells (PBMCs) were stimulated with various viral peptides and antigen-specific T-cell responses were evaluated using flow cytometry.
Results Booster vaccines induced CD8+ T-cell response against the ancestral SARS-CoV-2 strain and Omicron variant in both non-cancer subjects and patients with lung cancer, but only a marginal induction was detected for CD4+ T cells. Importantly, antigen-specific T cells from patients with lung cancer showed distinct subpopulation dynamics with varying degrees of differentiation compared with non-cancer subjects, with evidence of dysfunction. Notably, female-biased T-cell responses were observed.
Conclusion We conclude that patients with lung cancer on immunotherapy show a substantial qualitative deviation from non-cancer subjects in their T-cell response to mRNA vaccines, highlighting the need for heightened protective measures for patients with cancer to minimize the risk of breakthrough infection with the Omicron and other future variants.
논문정보
- Research article
- 2024년 01월 (BRIC 등록일 2024-01-15)
- 국외 연구진
댓글 작성 로그인
팝업 닫기관련 링크
